News

Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001

By Frontera News | September 21, 2022

China CDE accepts Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease. BEDFORD, Massachusetts, and SHANGHAI, China September 21, 2022 — Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of […]

Read More

Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities

By Frontera News | July 19, 2022

FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may result in blindness. Investors in the $160 million Series B round include Boyu Capital, Sequoia China, and existing investors OrbiMed and Creacion Ventures, who were […]

Read More